October 22, 2019


Avivagen announces first order for OxC-beta™ Livestock product in Taiwan
 

 

Avivagen Inc., a Canada-based life sciences corporation focused on developing and commercialising products for livestock, companion animals and human applications, has announced in early October that it has received its first order for the company's OxC-beta™ Livestock in Taiwan, specifically for use in poultry and sow feeds.


The 200 kilogramme order comes from More Standing Enterprise Co., Ltd., a leading manufacturer based in Taiwan of animal nutrition products for improving animal production efficiency in the premix industry in Taiwan and Southeast Asia. This introductory order comes after several successful testing programs.


"Today's new order is further evidence that feed producers around the world are recognising the substantial benefit that OxC-beta™ Livestock provides in improving the health and performance of multiple food producing animal species and allowing the phasing out of non-medicinal use of antibiotics," said Kym Anthony, CEO of Avivagen Inc.


"While reducing antibiotic use is a major benefit, customers are also recognising our product's positive impacts on aspects of animal performance that go beyond the antibiotic alternative role, improving the reproductive performance and milk quality of sows being a prime example


"With commercial use for sows now in place in multiple markets, we anticipate a considerable increase in short and long-term interest from and use in many more markets around the world."


With a total of nearly 3.25 million tonnes of sow feed and nearly 3.5 million tonnes of poultry feed produced annually, Taiwan represents a new growth market for Avivagen's OxC-beta™ Livestock product and expands its use across Asia Pacific.

 

Beyond Taiwan, use of OxC-beta™ Livestock has been ramping up steadily in the Philippines and Thailand, and Avivagen believes that the scale-up of OxC-beta™ Livestock use in Taiwan will mirror that of other markets in the region.

 

Use in sow feeds is of particular significance as it provides further commercial validation of research findings showing that OxC-beta™ Livestock positively impacts sow health, milk quality and the health of nursing piglets, Avivagen said.


Commercial validation in Taiwan follows the same validation in Thailand, and is expected to positively influence adoption for use in sows in other countries in both Asia Pacific and around the globe, according to the company.


OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the United States, the Philippines, Taiwan, Thailand, New Zealand, Mexico and Australia.


Avivagen intends to accelerate market access and the commercial uptake of its OxC-beta™ Livestock product, a product that has the potential to eliminate the use of antibiotics as growth promoters in livestock feed.


- Avivagen

Video >

Follow Us

FacebookTwitterLinkedIn